CalciMedica Common Stock is an intriguing investment option this February, especially when considering its financial fundamentals. With a robust Z Score of
72.48, the company demonstrates a low probability of financial distress in the near future. However, investors should be aware of its negative Return On Asset of
1.57%, indicating a loss in efficiency in managing its assets to generate earnings. This negative figure reflects the company's net loss from continuing operations, which stands at
$56.6M. While the biotechnology industry can be volatile, the
fundamentals of CalciMedica suggest there may be untapped potential for investors willing to navigate its challenges.
Main Takeaways
CalciMedica Common Stock has shown instability over a three-month investment horizon. The company's Sharpe Ratio, or Efficiency, stands at 0.25, indicating that the company has generated a 0.25% return per unit of risk over the past three months. When predicting the risk of a stock, it's crucial to use both market data and company-specific technical data. We have managed to analyze and interpret twenty-eight different technical indicators, which can assist you in determining if the anticipated returns of 1.92% are justified by the proposed risk. To evaluate company-specific risk that cannot be diversified away, use CalciMedica Common's Mean Deviation of 5.89, downside deviation of 7.57, and Risk Adjusted Performance of 0.1288.
Typically, a company's
financial statements are the reports that show the
financial position of the company. There are three main documents that fall into the category of financial statements. These documents include CalciMedica, Common income statement, its balance sheet, and the statement of cash flows. Potential CalciMedica, Common investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although CalciMedica, Common investors may use each financial statement separately, they are all related. The changes in CalciMedica, Common's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on CalciMedica, Common's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our
technical analysis and
fundamental analysis pages.
The goal of CalciMedica, Common
fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of CalciMedica, Common performance into the future periods or doing a reasonable stock valuation. The intrinsic value of CalciMedica, Common shares is the value that is considered the true value of the share. If
the intrinsic value of CalciMedica, is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares CalciMedica, Common. Please read more on our
fundamental analysis page.
How effective is CalciMedica, Common in utilizing its assets?
CalciMedica, Common Stock reports assets on its Balance Sheet. It represents the amount of CalciMedica, resources that either has an existing economic value or will provide some form of benefits in the future. By effectively utilizing its assets, CalciMedica, Common aims to generate revenue, control costs, drive operational efficiency, and enhance profitability. Optimizing asset utilization helps maximize shareholder value and maintain a competitive position in the Biotechnology space. To get a better handle on how balance sheet or income statements item affect CalciMedica, volatility, please check the breakdown of all its
fundamentals.
Are CalciMedica, Common Earnings Expected to grow?
The
future earnings power of CalciMedica, Common involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of CalciMedica, Common factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. CalciMedica, Common
stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of CalciMedica,
expected earnings.
CalciMedica, Common Gross Profit
CalciMedica, Common Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing CalciMedica, Common previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show CalciMedica, Common Gross Profit growth over the last 10 years. Please check CalciMedica, Common's
gross profit and other
fundamental indicators for more details.
An Additional Perspective On CalciMedica, Common Stock
Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of CalciMedica Common is not uncomon. Many companies such as CalciMedica Common have both institutions investors and insiders sharing the ownership. Retail investors typically buy and sell stocks in round lots of 100 shares or more. Other other hand institutional investors are known to buy and sell in block trades of 10,000 shares or more. Let's take a look at how the ownership of CalciMedica is distributed among investors.
Ownership Allocation
CalciMedica Common Stock retains a total of 5.68 Million outstanding shares. CalciMedica Common Stock retains significant amount of outstanding shares owned by
insiders. An
insider is usually defined as a CEO, other corporate executive, director, or
institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently
losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
| Retail Investors29.67% | Insiders21.54% | Institutions48.79% |
| Retail Investors | 29.67 |
| Insiders | 21.54 |
| Institutions | 48.79 |
Please be aware that individual investors typically purchase shares for their personal accounts and usually in smaller quantities compared to institutional investors. While they might influence CalciMedica Common's decisions if they own a significant combined portion of its shares, such influence is relatively rare. Conversely, institutional investors - like mutual funds, pension funds, hedge funds, and other investment companies - often have a substantial sway over CalciMedica Common's decisions due to their larger holdings.
Asset Utilization
One of the ways to look at asset utilization of CalciMedica is to check how much profit was generated for every dollar of assets it reports. CalciMedica Common Stock shows a negative utilization of assets of -1.57 percent, losing USD0.0157 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of CalciMedica Common Stock shows how discouraging it operates for each dollar spent on its assets.
| Current Assets2 M | Assets Non Current2 M |
| Current Assets | 2.04 Million | 50.21 |
| Assets Non Current | 2.02 Million | 49.79 |
As Benjamin Graham once said, the stock market is a voting machine in the short term, but a weighing machine in the long term. With this in mind, let's delve into the
fundamentals of CalciMedica Common Stock, a NASDAQ-listed biotechnology company. Despite an operating income loss of $55.9M and a net income loss of $56.6M, the company has a working capital of $35.97M and a cash reserve of $17.3M, indicating potential for recovery and growth. The company's market capitalization stands at $27.18M, while its net assets are valued at $39.67M, suggesting that the stock may be undervalued. However, the company's high total operating expenses of $55.9M and a negative return on assets of 1.57, coupled with a negative enterprise value of $14.7M, may be cause for concern. Despite these challenges, with a target price of $10.13 and a current price-to-book ratio of 1.9948, CalciMedica's stock could still offer untapped potential for investors this February.
Another 3 percent surge for CalciMedica Common
Despite the risk-adjusted performance of CalciMedica Common Stock falling to 0.13 as of today, the stock has managed to climb an additional 3 percent. This suggests that the company continues to yield a positive return for its investors, even amidst heightened
market volatility and risk. The durability of CalciMedica's stock in such a demanding environment emphasizes the company's strong
fundamentals and its potential for continued growth. Therefore, investors might consider holding onto their positions or even increasing their stakes in CalciMedica Common Stock. As of January 20th, CalciMedica Common Stock shows a Mean Deviation of 5.89, a downside deviation of 7.57, and a Risk Adjusted Performance of 0.1288. Technical analysis of CalciMedica Common Stock provides a methodology to utilize historical prices and volume patterns to predict a pattern that approximates the direction of the company's future prices. In other words, this information can be used to determine if the company will indeed reflect its model of historical prices and volume momentum, or if the prices will eventually revert. We were able to analyze and interpolate nineteen technical drivers for CalciMedica Common Stock, which can be compared to its
competitors. Please verify CalciMedica Common Stock's Treynor Ratio, and the relationship between the variance and potential upside to decide if CalciMedica Common Stock is priced correctly, considering its regular price of 4.78 per share.
Given that CalciMedica Common has a Jensen Alpha of 1.21, we recommend you to validate CalciMedica Common Stock's current market performance to ensure the company can sustain itself in the future. In conclusion, CalciMedica, Inc., a clinical-stage biotechnology company, presents a compelling investment opportunity. The company's focus on developing therapies for life-threatening inflammatory diseases with unmet needs is a strong value proposition. The
analyst consensus is a
Strong Buy, with the highest, lowest, and estimated target price all standing at
$14. This represents a significant upside from the current market valuation of $4.78. Furthermore, the company's valuation real value is $6.81, indicating potential for growth. The company's fiscal year ends in December, providing investors with a clear timeline for evaluating performance. However, investors should be aware of the company's valuation hype value of 4.57, which may indicate over-excitement in the market. Overall, CalciMedica Common Stock appears to be a promising investment for February. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of CalciMedica, Common Stock. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com